RIG‐I Mediated Neuron‐Specific IFN Type 1 Signaling in FUS‐ALS Induces Neurodegeneration and Offers New Biomarker‐Driven Individualized Treatment Options for (FUS‐)ALS
Advanced Science · 2026
DOI: 10.1002/advs.202417135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Marcel Naumann und 26 weiteren Autor:innen. Beteiligte Einrichtung: Translational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock…. Hauptthemen laut MEDLINE: Receptors, Immunologic, Amyotrophic Lateral Sclerosis, DEAD Box Protein 58, Motor Neurons. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation (DFG), German Federal Ministry of Education and Research (BMBF), Stichting ALS Nederland.
Abstract (Originalsprache)
Recent research demonstrated activation of the innate immune system in ALS models. This pathway can be activated by cGAS‐STING sensing of cytosolic DNA that accumulates as a result of chronic DNA damage and defective mitochondria, both of which was identified as pathology in FUS‐ALS. Therefore, we analyzed innate immune pathways in FUS‐ALS, which revealed upregulation of interferon‐stimulated genes (ISGs) and activation of the TBK1‐IRF3 pathway in FUS mut iPSC‐derived spinal motor neurons (sMNs). Accumulation of cytosolic dsRNA and its sensor RIG‐I, but not MDA5, was found to be significantly upregulated in FUS mut sMNs, which was abolished upon siRNA‐mediated knockdown of RIG‐I. RIG‐I was highly expressed in FUS‐ALS post‐mortem α‐MNs. IFN treatment of FUS wt sMNs phenocopied the axonal degeneration of FUS mut sMNs. Mitochondrial transcription, a known source of dsRNA, was found to be upregulated in compartmental axonal RNAseq analysis and its inhibition reduced ISGs in FUS‐ALS sMNs. The JAK‐STAT inhibitor ruxolitinib alleviated the upregulated ISG expression and reversed the axonal degeneration of sMNs. Finally, we analyzed ISG expression in peripheral blood from 18 FUS‐ALS patients, eight of whom had a significantly elevated interferon signature. RIG‐I‐mediated innate immune activation in sMNs may be an interesting novel individualized biomarker‐driven therapeutic target in (FUS‐) ALS. A one‐sentence summary of your paper : RIG‐I‐mediated innate immune activation is found in FUS‐ALS spinal motor neurons caused by cytosolic dsRNA accumulation due to mitochondrial transcriptional activation and is amenable to JAK‐STAT inhibition and might thus be an interesting novel individualized biomarker‐driven therapeutic approach in (FUS‐) ALS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.
- Department of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
- Department of Neurology, Sean M. Healey & AMG Center for ALS, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Center For Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, University of Rostock, Rostock, Germany.
- Department of Neurology, University Hospital Carl Gustav Carus At Technische Universität Dresden, Dresden, Germany.
- German Center for Neurodegenerative DIseases (DZNE) Dresden, Dresden, Germany.
ORCID-Profile: Andreas Hermann
Förderung
- German Research Foundation (DFG)
- German Federal Ministry of Education and Research (BMBF)
- Stichting ALS Nederland
- Hermann und Lilly Schilling-Stiftung für Medizinische Forschung
- Clinician Scientist program of the Medical Faculty of the University of Rostock (RAS)
Zitieren
APA
Naumann, M., Wierschin, T. M., Kretschmer, S., Dash, B. P., Held, A., Salzinger, A., Peikert, K., Karlek, A., Glaß, H., Großmann, D., Günther, R., Petri, S., Rödiger, A., Brenner, D., Pan-Montojo, F., Aronica, E., Kipp, M., Zimyanin, V., Sterneckert, J., …, & Hermann, A. (2026). RIG‐I Mediated Neuron‐Specific IFN Type 1 Signaling in FUS‐ALS Induces Neurodegeneration and Offers New Biomarker‐Driven Individualized Treatment Options for (FUS‐)ALS. Advanced Science. https://doi.org/10.1002/advs.202417135
Vancouver
Naumann M, Wierschin TM, Kretschmer S, Dash BP, Held A, Salzinger A, et al. RIG‐I Mediated Neuron‐Specific IFN Type 1 Signaling in FUS‐ALS Induces Neurodegeneration and Offers New Biomarker‐Driven Individualized Treatment Options for (FUS‐)ALS. Advanced Science. 2026. doi:10.1002/advs.202417135
BibTeX
@article{Naumann2026,
author = {Naumann, Marcel and Wierschin, Theresa M and Kretschmer, Stefanie and Dash, Banaja P and Held, Aaron and Salzinger, Andrea and Peikert, Kevin and Karlek, Anže and Glaß, Hannes and Großmann, Dajana and Günther, René and Petri, Susanne and Rödiger, Annekathrin and Brenner, David and Pan-Montojo, Francisco and Aronica, Eleonora and Kipp, Markus and Zimyanin, Vitaly and Sterneckert, Jared and Grehl, Torsten and Seebacher, Noah D and Böckers, Tobias M and Catanese, Alberto and Wainger, Brian J and Oeckl, Patrick and Lee-Kirsch, Min Ae and Hermann, Andreas},
title = {RIG‐I Mediated Neuron‐Specific IFN Type 1 Signaling in FUS‐ALS Induces Neurodegeneration and Offers New Biomarker‐Driven Individualized Treatment Options for (FUS‐)ALS},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202417135}
}
EUVIMED